RVMD Revolution Medicines, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1628171 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-94.6%
TTM EPS YoY-75.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-93.6%
ROA-57.1%
ROIC (approx.)-84.1%
Asset turnover—
Leverage & solvency
Liabilities / assets44.2%
Debt / equity0.00x
Current ratio8.36x
Interest coverage-20.62x
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-13.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $197.56M | — | — | $0 | $0 | — | — | $0 |
| Cost of revenue | $327,000 | — | — | — | $0 | — | — | — |
| Gross profit | $197.23M | — | — | — | $0 | — | — | — |
| R&D expense | $417.09M | $394.92M | $343.97M | $294.94M | $262.51M | $224.13M | $205.75M | $188.10M |
| SG&A expense | $153.29M | $110.21M | $101.25M | $66.68M | $52.76M | $40.58M | $35.01M | $28.21M |
| Operating income | -$373.15M | -$505.13M | -$445.22M | -$361.63M | -$315.27M | -$264.71M | -$240.76M | -$216.31M |
| Interest expense | $33.80M | $23.78M | $12.20M | $11.94M | $11.43M | $867,000 | $0 | $0 |
| Pretax income | -$409.81M | -$644.37M | -$453.82M | -$364.89M | -$305.21M | -$247.79M | -$213.42M | -$195.32M |
| Income tax | -$2.35M | — | — | $0 | $0 | — | — | -$753,000 |
| Net income | -$407.46M | -$644.37M | -$453.82M | -$364.89M | -$305.21M | -$247.79M | -$213.42M | -$194.57M |
| EBITDA | -$370.85M | -$503.03M | -$442.88M | -$359.36M | -$313.27M | -$263.01M | -$239.07M | -$214.57M |
| EPS (basic) | -1.90 | -3.06 | -2.29 | — | -1.61 | -1.31 | -1.13 | — |
| EPS (diluted) | -1.90 | -3.06 | -2.29 | — | -1.61 | -1.31 | -1.13 | — |
| Weighted avg. shares (diluted) | 214.95M | 210.89M | 198.10M | — | 189.23M | 188.58M | 188.15M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $615.91M | $815.43M | $440.94M | $383.75M | $217.44M | $402.44M | $333.55M | $543.06M |
| Short-term investments | $3.04B | $3.12B | $1.47B | $1.64B | $1.71B | $1.73B | $1.77B | $1.75B |
| Receivables | $230.72M | — | — | $0 | — | — | — | — |
| Inventory | $11.02M | — | — | $0 | — | — | — | — |
| Current assets | $3.98B | $4.03B | $1.97B | $2.08B | $1.98B | $2.18B | $2.13B | $2.33B |
| PP&E, net | $34.63M | $34.61M | $31.48M | $33.19M | $32.93M | $33.05M | $27.15M | $24.29M |
| Goodwill | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M | $14.61M |
| Intangibles | $55.47M | $55.80M | $55.80M | $55.80M | $55.87M | $56.14M | $56.40M | $56.67M |
| Total assets | $4.30B | $4.32B | $2.25B | $2.35B | $2.25B | $2.43B | $2.37B | $2.56B |
| Current liabilities | $475.67M | $354.06M | $289.60M | $290.42M | $245.62M | $184.53M | $158.60M | $163.91M |
| Total liabilities | $1.90B | $1.72B | $753.82M | $723.21M | $655.02M | $564.20M | $287.20M | $293.10M |
| Shareholders' equity | $2.40B | $2.61B | $1.50B | $1.63B | $1.60B | $1.87B | $2.08B | $2.27B |
| Shares outstanding | 216.25M | 214.24M | 200.18M | 197.00M | 189.71M | 186.90M | 186.26M | 185.90M |
| Cash flow statement | ||||||||
| Operating cash flow | -$415.65M | -$387.32M | -$354.17M | -$274.24M | -$207.31M | -$221.76M | -$194.44M | -$138.29M |
| Capital expenditure | $3.70M | $2.29M | $1.54M | $1.93M | $3.35M | $7.45M | $3.27M | $1.22M |
| Free cash flow | -$419.35M | -$389.61M | -$355.70M | -$276.16M | -$210.66M | -$229.21M | -$197.70M | -$139.51M |
| Investing cash flow | $80.10M | -$1.66B | $172.62M | $74.88M | $24.85M | $34.28M | -$15.95M | -$392.90M |
| Financing cash flow | $147.00M | $2.42B | $238.74M | $365.66M | -$1.59M | $256.58M | $874,000 | $873.80M |
| Depreciation & amortization | $2.30M | $2.10M | $2.35M | $2.27M | $2.00M | $1.70M | $1.69M | $1.74M |
| Stock-based compensation | $62.15M | $67.00M | $87.30M | $33.70M | $30.78M | $28.83M | $25.08M | $22.44M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.